Mirum Pharmaceuticals Stock Performance
| MIRM Stock | USD 48.44 0.44 0.90% |
On a scale of 0 to 100, Mirum Pharmaceuticals holds a performance score of 10. The company secures a Beta (Market Risk) of 0.0512, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Mirum Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Mirum Pharmaceuticals is expected to be smaller as well. Please check Mirum Pharmaceuticals' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Mirum Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Mirum Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Mirum Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.91 | Five Day Return 3.14 | Year To Date Return 16.27 | Ten Year Return 270.02 | All Time Return 270.02 |
1 | Leerink Partnrs Has Positive Outlook of MIRM FY2024 Earnings | 11/15/2024 |
2 | Acquisition by Longpre Lara of 434 shares of Mirum Pharmaceuticals at 22.287 subject to Rule 16b-3 | 12/19/2024 |
3 | Mirum Pharmaceuticals Inc to Present at J.P. Morgan Healthcare Conference | 01/06/2025 |
4 | Disposition of 750 shares by Howe Jolanda of Mirum Pharmaceuticals at 42.8153 subject to Rule 16b-3 | 01/07/2025 |
5 | Disposition of 1379 shares by Pamela Vig of Mirum Pharmaceuticals at 20.6223 subject to Rule 16b-3 | 01/08/2025 |
6 | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 01/10/2025 |
7 | Mirum Pharmaceuticals Inc Announces 2024 Achievements and 2025 Outlook | 01/13/2025 |
8 | Axsome Moves 11.5 percent Higher Will This Strength Last | 01/14/2025 |
9 | Acquisition by Quan Joanne of 12500 shares of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/16/2025 |
10 | Disposition of 6969 shares by Quan Joanne of Mirum Pharmaceuticals at 45.86 subject to Rule 16b-3 | 01/17/2025 |
11 | Acquisition by Christopher Peetz of 38390 shares of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/21/2025 |
12 | Disposition of 12500 shares by Christopher Peetz of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/23/2025 |
13 | Disposition of 6837 shares by Christopher Peetz of Mirum Pharmaceuticals at 47.9243 subject to Rule 16b-3 | 01/24/2025 |
14 | Mirum Pharmaceuticals stock soars to all-time high of 48.94 - MSN | 01/29/2025 |
| Begin Period Cash Flow | 128 M |
Mirum |
Mirum Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 4,045 in Mirum Pharmaceuticals on November 4, 2024 and sell it today you would earn a total of 799.00 from holding Mirum Pharmaceuticals or generate 19.75% return on investment over 90 days. Mirum Pharmaceuticals is currently generating 0.3312% in daily expected returns and assumes 2.4881% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Mirum, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mirum Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mirum Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mirum Pharmaceuticals, and traders can use it to determine the average amount a Mirum Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1331
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MIRM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.49 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Mirum Pharmaceuticals is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mirum Pharmaceuticals by adding it to a well-diversified portfolio.
Mirum Pharmaceuticals Fundamentals Growth
Mirum Stock prices reflect investors' perceptions of the future prospects and financial health of Mirum Pharmaceuticals, and Mirum Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mirum Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.091 | ||||
| Profit Margin | (0.33) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 2.38 B | ||||
| Shares Outstanding | 48 M | ||||
| Price To Earning | (5.20) X | ||||
| Price To Book | 10.11 X | ||||
| Price To Sales | 7.64 X | ||||
| Revenue | 186.37 M | ||||
| Gross Profit | 223.14 M | ||||
| EBITDA | (136.49 M) | ||||
| Net Income | (163.41 M) | ||||
| Cash And Equivalents | 124.95 M | ||||
| Cash Per Share | 3.82 X | ||||
| Total Debt | 308.14 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.26 X | ||||
| Book Value Per Share | 4.84 X | ||||
| Cash Flow From Operations | (70.94 M) | ||||
| Earnings Per Share | (2.08) X | ||||
| Market Capitalization | 2.35 B | ||||
| Total Asset | 646.62 M | ||||
| Retained Earnings | (556.24 M) | ||||
| Working Capital | 300.48 M | ||||
| Current Asset | 106.8 M | ||||
| Current Liabilities | 11.7 M | ||||
About Mirum Pharmaceuticals Performance
By examining Mirum Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Mirum Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mirum Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 199.10 | 230.08 | |
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.22) | (0.24) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.76) | (0.72) |
Things to note about Mirum Pharmaceuticals performance evaluation
Checking the ongoing alerts about Mirum Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mirum Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 186.37 M. Net Loss for the year was (163.41 M) with profit before overhead, payroll, taxes, and interest of 223.14 M. | |
| Mirum Pharmaceuticals currently holds about 124.95 M in cash with (70.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.82. | |
| Mirum Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Mirum Pharmaceuticals stock soars to all-time high of 48.94 - MSN |
- Analyzing Mirum Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mirum Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Mirum Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mirum Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mirum Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mirum Pharmaceuticals' stock. These opinions can provide insight into Mirum Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 0.894 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.